Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights customer receipts and a positive net cash flow from operations, alongside significant progress in clinical trials and new technology developments. The company reported unaudited revenue for the first half of the fiscal year, indicating strong performance across its business segments.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Resonance Health
- AGM Presentation
- Investor Strategy Day Presentation
- FY25 Full Year Results & FY26 Guidance Investor Presentation
- Appendix 4E & Full Year Statutory Accounts
- TrialsWest Expands with New Clinical Trial Site
Later from Resonance Health
- Half Year Report & Accounts
- Half Year Results
- Half Year Results Presentation
- Receipt of R&D Tax Incentive Refund
- Profit Guidance Upgrade
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health